[1] 李狄航,梁运升. 乳腺癌分子分型及其临床治疗意义[J]. 中国基层医药, 2018,25(17):2309-2312. Li D H,Liang Y S. The molecular subtyping of breast cancer and its clinical treatment significance[J]. Chinese Journal of Primary Medicine and Pharmacy, 2018,25(1):2309-2312.
[2] Kuzmiak C M. A radiologist's guide to breast cancer genomics[J]. Contemporary Diagnostic Radiology, 2018,41(3):112-116.
[3] Allarakha A,高燕,王培军.乳腺癌MRI诊断进展[J].中国医学影像技术,2018,34(2):306-309. Allarakha A, Gao Y,Wang P J. Progresses of MRI diagnosis in breast cancer[J]. Chinese Journal of Medical Imaging Technology, 2018,34(2):306-309.
[4] 蒙茗, 薛华丹, 李媛, 等. 弥散加权成像体素内不相干运动模型在乳腺癌诊疗中的应用进展[J]. 中国医学科学院学报,2017,39(4):583-586. Meng M, Xue H D, Li Y, et al. Application of intravoxel incoherent motion model-based diffusion weighted imaging in the diagnosis and therapy of breast cancer[J]. Acta Academiae Medicinae Sinicae, 2017,39(4):583-586.
[5] 孙双燕, 杨长良, 黄志成,等. 不同分子亚型乳腺癌MRI特征分析[J]. 中国临床医学影像杂志, 2017,28(5):327-330. Sun S Y, Yang C L, Huang Z C, et al. MRI features of different molecular subtypes of breast cancer[J]. Journal of China Clinic Medical Imaging, 2017,28(5):327-330.
[6] Kawashima H, Miyati T, Ohno N, et al. Differentiation between Luminal-A and Luminal-B breast cancer using intravoxel incoherent motion and dynamic contrast-enhanced magnetic resonance imaging[J]. Academic Radiology, 2017,24(12):1575-1581.
[7] Cen D, Hu W, Wang X, et al. Re:identification of preoperative magnetic resonance imaging features associated with positive resection margins in breast cance[J]. Korean Journal of Radiology, 2019,20(6):999-1000.
[8] 凌公豪,范晨虹,龙清云, 等.体素内不相干运动扩散加权成像定量参数在肝脏良恶性病变诊断中的价值[J].临床放射学杂志,2018,37(3):536-540. Ling G H,Fan C H, Long Q Y, et al. Study on diagnosis value of intravoxel incoherent motion DWI in hepatic lesions[J]. Journal of Clinical Radiology, 2018,37(3):536-540.
[9] 宋萌萌, 张天月, 王丽君,等. IVIM多参数预测乳腺癌免疫组化指标表达的可行性研究[J].磁共振成像, 2017, 8(3):170-175. Song M M,Zhang T Y, Wang L J, et al. The feasibility of intravoxel incoherent motion to indicate immunohistochemical characteristics in breast cancer[J]. Chinese Journal of Magnetic Resonance Imaging, 2017,8(3):170-175.
[10] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2015年版)[J]. 中国癌症杂志, 2015,25(9):641-703. Chinese Anti-cancer Association, Committee of Breast Cancer Society.Guidelines and specifications for the diagnosis and treatment of breast cancer of the China Anticancer Association (2015 edition)[J]. China Oncology, 2015,25(9):641-703.
[11] 中华人民共和国国家卫生和计划生育委员会. 原发性乳腺癌规范化诊疗指南(试行)[J]. 中国医学前沿杂志(电子版), 2013,5(5):30-37. National Health and Family Planning Commission of China. Guidelines for the standardized diagnosis and treatment of primary breast cancer (Try out)[J]. Chinese Journal of the Frontiers of Medical Science (Electronic Version), 2013,5(5):30-37.
[12] 吴莹, 洪晏,谢轶群,等.ER/PR和HER2-型乳腺癌患者免疫组化指标的列线图预后模型[J].中国肿瘤生物治疗杂志, 2018,25(9):934-939. Wu Y,Hong Y, Xie Y Q, et al.A prognostic nomogram for ER/PR+ and HER2-breast cancer patients based on classical immunohistochemical index[J].Chinese Journal of Cancer Biotherapy, 2018,25(9):934-939.
[13] 刘月平, 步宏, 杨文涛. 2019版中国乳腺癌HER2检测指南更新解读[J]. 中华病理学杂志, 2019,48(3):182-185. Liu Y P,Bu H, Yang W T.Interpretation of 2019 update of Chinese breast cancer HER2 detection guidelines[J].Chinese Journal of Pathology, 2019,48(3):182-185.
[14] 马海明,刘涛,刘晓康,等.乳腺癌组织Ki-67和HER2及PHH3表达与新辅助化疗疗效相关性分析[J].中华肿瘤防治杂志, 2018,25(10):709-712. Ma H M, Liu T, Liu X K, et al. Study of molecular markers to predict the effect of neoadjuvant chemotherapy on breast cancer in advanced stage[J]. Chinese Journal of Cancer Prevention and Treatment, 2018,25(10):709-712.
[15] Jordan L G, Booth B W. HER2+ breast cancer cells undergo apoptosis upon exposure to tannic acid released from remodeled cross-linked collagen type I[J]. Journal of Biomedical Materials Research Part A, 2018,106(1):26-32.
[16] 孙瑞红,蒋朝霞,孟凡华, 等.体素内不相干运动成像鉴别乳腺良恶性病变的价值并与定量动态增强MRI对比[J].中国癌症杂志,2017,27(10):795-800. Sun R H, Jiang C X, Meng F H, et al. Differentiation of benign and malignant breast lesions:a comparative study of intravoxel incoherent motion and quantitative dynamic contrast enhanced-magnetic resonance imaging[J]. China Oncology, 2017,27(10):795-800.
[17] Mukherjee S D, Hodgson N, Lovrics P J, et al. Surgical attitudes toward preoperative breast magnetic resonance imaging in women with early-stage breast cancer[J].Current Oncology, 2019,26(2):e194-e201.
[18] Youn I, Choi S H, Choi Y J,et al. Contrast enhanced digital mammography versus magnetic resonance imaging for accurate measurement of the size of breast cancer[J]. British Journal of Radiology, 2019,92(1098):20180929.
[19] Li J, Zhu P, Wang L, et al. Study of diffusion-weighted magnetic resonance imaging in the evaluation of the response to AAV2-VEGF-Trap neoadjuvant treatment in a triple-negative breast cancer animal model[J].Cancer Medicine, 2019,8(4):1594-1603.
[20] Krontiras H, Farmer M, Whatley J. Breast cancer genetics and indications for prophylactic mastectomy[J]. Surgical Clinics North America, 2018,98(4):677-685.
[21] Ko E S, Morris E A. Abbreviated magnetic resonance imaging for breast cancer screening:concept, early resuits, and considerations[J]. Korean Journal Radiology, 2019,20(4):533-541.
[22] Kitajima K, Yamano T, Miyoshi Y, et al. Prognostic value of (18)F-FDG PET/CT prior to breast cancer treatment. comparison with magnetic resonance spectroscopy and diffusion weighted imaging[J].Hellenic Journal of Nuclear Medicine, 2019,22(1):25-35.
[23] Fogante M, Tagliati C, De Lisa M, et al. Correlation between apparent diffusion coefficient of magnetic resonance imaging and tumor-infiltrating lymphocytes in breast cancer[J].La Radiologia Medica, 2019,124(7):581-587.
[24] Indolfi C, Cappabianca S, Rossi F, et al. Abbreviated breast magnetic resonance imaging (FAST-MRI):a novel approach to breast cancer screening in patients with previous Hodgkin lymphoma[J].Pediatric Blood & Cancer, 2019,66(6):e27666.
[25] Gampenrieder S P, Peer A, Weismann C, et al. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR)[J]. Breast Cancer Research, 2019,21:19. |